BNGO Bionano Genomics, Inc. logo

BNGO Bionano Genomics, Inc.

Healthcare
$1.24+0.81%ClosedMarket Cap: $4.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.18

P/S

0.14

EV/EBITDA

-0.32

DCF Value

$-119.55

FCF Yield

-474.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

47.0%

Operating Margin

-114.0%

Net Margin

-109.9%

ROE

-71.4%

ROA

-48.8%

ROIC

-60.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$6.7M$-8.3M$
Q4 null$8.0M$-7.9M$
FY null$28.5M$-26.4M$
Q3 null$7.4M$-8.5M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$46.50

Target (Median)

$5.00

Target Range

$1.00 - $175.00

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-04-13
HC Wainwright & Co.Buy
2025-11-24
HC Wainwright & Co.Buy
2025-08-18

Trading Activity

Insider Trades

View All
Vuori Kristiina MDdirector
SellThu May 14
TWOMEY CHRISTOPHER Jdirector
SellThu May 14
Rajkovic Aleksandardirector
SellThu May 14
Linney Yvonnedirector
SellThu May 14
BARKER DAVID Ldirector
SellThu May 14

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.62

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Peers